CA2959793A1 - Methods of treating alpha adrenergic mediated conditions - Google Patents

Methods of treating alpha adrenergic mediated conditions Download PDF

Info

Publication number
CA2959793A1
CA2959793A1 CA2959793A CA2959793A CA2959793A1 CA 2959793 A1 CA2959793 A1 CA 2959793A1 CA 2959793 A CA2959793 A CA 2959793A CA 2959793 A CA2959793 A CA 2959793A CA 2959793 A1 CA2959793 A1 CA 2959793A1
Authority
CA
Canada
Prior art keywords
dihydro
amine
imidazol
pain
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2959793A
Other languages
English (en)
French (fr)
Inventor
Wenkui K. Fang
Phong X. Nguyen
Ken Chow
Todd M. Heidelbaugh
Dario G. Gomez
Michael E. Garst
Santosh C. Sinha
Daniel W. Gil
John E. Donello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to CA3133261A priority Critical patent/CA3133261A1/en
Publication of CA2959793A1 publication Critical patent/CA2959793A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
CA2959793A 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions Abandoned CA2959793A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3133261A CA3133261A1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5983708P 2008-06-09 2008-06-09
US61/059,837 2008-06-09
CA2744929A CA2744929C (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2744929A Division CA2744929C (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3133261A Division CA3133261A1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions

Publications (1)

Publication Number Publication Date
CA2959793A1 true CA2959793A1 (en) 2009-12-17

Family

ID=40823137

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2959793A Abandoned CA2959793A1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions
CA2744929A Active CA2744929C (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions
CA3133261A Abandoned CA3133261A1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2744929A Active CA2744929C (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions
CA3133261A Abandoned CA3133261A1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions

Country Status (14)

Country Link
US (2) US8071636B2 (https=)
EP (3) EP2303264B1 (https=)
JP (1) JP5571072B2 (https=)
CN (1) CN102099032B (https=)
AU (1) AU2009257692A1 (https=)
CA (3) CA2959793A1 (https=)
DK (2) DK2932968T3 (https=)
ES (2) ES2672777T3 (https=)
HU (1) HUE039357T2 (https=)
PL (2) PL2303264T3 (https=)
PT (2) PT2303264T (https=)
SI (1) SI2303264T1 (https=)
TR (1) TR201802766T4 (https=)
WO (1) WO2009152052A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
PL2605771T3 (pl) * 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych
JP6756435B2 (ja) * 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア
EP3700536A4 (en) 2017-10-27 2021-11-17 Shanghai Yao Yuan Biotechnology Co., Ltd. COMPOSITIONS AND PROCEDURES FOR MODULATING IMMUNE REACTION BY ACTIVATING ALPHA-PROTEIN KINASE 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6708160A (https=) * 1966-06-30 1968-01-02
DE2259160A1 (de) * 1972-12-02 1974-06-06 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel
US4256755A (en) 1980-04-28 1981-03-17 E. I. Du Pont De Nemours & Company Method of using N-substituted dihydro-2-oxazolamines as analgesics
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
EP1333028A1 (en) * 2002-01-31 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
CN101287366A (zh) 2005-05-19 2008-10-15 拜尔农作物科学股份公司 杀虫的取代的苄基氨基杂环及杂芳基衍生物
WO2008123821A1 (en) * 2007-03-01 2008-10-16 Albireo Ab 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
CN101687812A (zh) * 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists

Also Published As

Publication number Publication date
PT2932968T (pt) 2018-03-13
EP2932968B1 (en) 2018-01-17
AU2009257692A1 (en) 2009-12-17
DK2303264T3 (en) 2018-05-22
EP2303264A1 (en) 2011-04-06
US8071636B2 (en) 2011-12-06
JP5571072B2 (ja) 2014-08-13
WO2009152052A8 (en) 2010-11-11
WO2009152052A1 (en) 2009-12-17
CA2744929C (en) 2017-07-25
JP2011522893A (ja) 2011-08-04
TR201802766T4 (tr) 2018-03-21
PL2303264T3 (pl) 2018-08-31
ES2665293T3 (es) 2018-04-25
EP2932968A1 (en) 2015-10-21
ES2672777T3 (es) 2018-06-18
HK1214132A1 (en) 2016-07-22
PL2932968T3 (pl) 2018-06-29
US20090306161A1 (en) 2009-12-10
CA3133261A1 (en) 2009-12-17
CN102099032B (zh) 2014-07-09
EP2303264B1 (en) 2018-04-04
CN102099032A (zh) 2011-06-15
EP2377534A1 (en) 2011-10-19
SI2303264T1 (en) 2018-08-31
DK2932968T3 (en) 2018-03-12
PT2303264T (pt) 2018-05-14
HUE039357T2 (hu) 2018-12-28
CA2744929A1 (en) 2009-12-17
US20120035235A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
JP4698591B2 (ja) 非鎮静ａ−２アゴニスト１−（２，３−ジメチル−フェニル）−エチル−１、３−ジヒドロ−イミダゾール−２−チオン
US20230062049A1 (en) Methods of treating alpha adrenergic mediated conditions
JP2007505112A (ja) 改善された非沈静α２アゴニストを同定するための新規方法
AU2024201553B2 (en) Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
JP2013540749A (ja) ［３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ
CA2931836C (en) P-substituted asymmetric ureas and medical uses thereof
CA2744929C (en) Methods of treating alpha adrenergic mediated conditions
TW200922584A (en) Organic compounds
US8063231B2 (en) Methods of treating alpha adrenergic mediated conditions
US20080242657A1 (en) Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
HK1162960A (en) Methods of treating alpha adrenergic mediated conditions
HK1155400B (en) Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives
HK1155400A (en) Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives
HK1214132B (en) Compound for treating alpha adrenergic mediated conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170302

FZDE Discontinued

Effective date: 20220928